全文获取类型
收费全文 | 520篇 |
免费 | 34篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 16篇 |
妇产科学 | 15篇 |
基础医学 | 39篇 |
口腔科学 | 3篇 |
临床医学 | 77篇 |
内科学 | 161篇 |
皮肤病学 | 7篇 |
神经病学 | 13篇 |
特种医学 | 6篇 |
外科学 | 30篇 |
综合类 | 21篇 |
预防医学 | 56篇 |
眼科学 | 16篇 |
药学 | 58篇 |
中国医学 | 4篇 |
肿瘤学 | 37篇 |
出版年
2023年 | 6篇 |
2022年 | 4篇 |
2021年 | 8篇 |
2020年 | 17篇 |
2019年 | 1篇 |
2018年 | 6篇 |
2017年 | 7篇 |
2016年 | 6篇 |
2015年 | 18篇 |
2014年 | 6篇 |
2013年 | 12篇 |
2012年 | 38篇 |
2011年 | 39篇 |
2010年 | 13篇 |
2009年 | 15篇 |
2008年 | 37篇 |
2007年 | 36篇 |
2006年 | 33篇 |
2005年 | 32篇 |
2004年 | 56篇 |
2003年 | 62篇 |
2002年 | 44篇 |
2001年 | 35篇 |
2000年 | 5篇 |
1999年 | 4篇 |
1998年 | 2篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 3篇 |
1964年 | 1篇 |
排序方式: 共有560条查询结果,搜索用时 31 毫秒
1.
Parallel enzyme‐linked immunosorbent assay screening for human immunodeficiency virus among blood donors in five Chinese blood centres: a retrospective analysis 下载免费PDF全文
2.
医院综合效益评价案例分析 总被引:2,自引:0,他引:2
西南地区医院综合效益评价课题组 《中国医院管理》1994,14(2):32-35
运用层次分析法建立了医院综合效益评价指标体系,开发了医院综合效益九型评价图,用于显著评价结果。在此基础上进行了3个案例的评价分析。论述了通过对西南地区27所医院综合效益4年多的追踪分析所发现的共性问题,并提出了相应的管理对策。 相似文献
3.
M. O. Bachmann M. O'Brien † C. Husbands ‡ A. Shreeve § N. Jones ¶ J. Watson § R. Reading J. Thoburn † M. Mugford the National Evaluation of Children's Trusts Team 《Child: care, health and development》2009,35(2):257-265
Background Poor co‐ordination of services can have severe consequences for disadvantaged children with complex needs. Since 2003 national and local governments in England embarked on sweeping reforms aimed at improving and integrating local health, education and social services for children. These were to be organized locally by children's trusts and piloted by 35 children's trust pathfinders. Methods This study described and compared the experience of integrating children's services in all 35 children's trust pathfinders, covering 20% of children in England. It had a prospective mixed‐methods design. Over 3 years we interviewed 147 managers and professionals working in the children's trusts, including 172 semi‐structured interviews, carried out two questionnaire surveys of the 35 children's trusts and analysed official documents. Results In most areas different agencies jointly commissioned children's services, especially for mental health, disabilities and multi‐purpose children's centres, and increasingly pooled finances. Provision of multi‐agency and multi‐professional services was increasing. Professionals generally supported these changes but found them stressful. All children's trusts appointed directors of children's services and established boards representing multiple agencies. Systems for sharing information about individual children were mostly in place but were still underused. Health services were generally less involved in joint work than were local authorities' education and social care services, with notable exceptions. Areas where local authorities and health authorities shared geographical boundaries made most progress. Some children's trusts made few changes beyond their statutory obligations. Conclusion Children's trusts enabled major changes to services in areas where local actors and organizations were motivated and empowered. In other areas the remit of children's trusts was often too broad and vague to overcome entrenched organizational and professional divisions and interests. Policymakers need to balance facilitation of change in areas with dynamic change agents with methods for ensuring that dormant areas and agencies are not left behind. 相似文献
4.
5.
Malone FD Canick JA Ball RH Nyberg DA Comstock CH Bukowski R Berkowitz RL Gross SJ Dugoff L Craigo SD Timor-Tritsch IE Carr SR Wolfe HM Dukes K Bianchi DW Rudnicka AR Hackshaw AK Lambert-Messerlian G Wald NJ D'Alton ME;First- Second-Trimester Evaluation of Risk 《The New England journal of medicine》2005,353(19):2001-2011
6.
Efficacy and safety of recombinant human activated protein C for severe sepsis 总被引:168,自引:0,他引:168
Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Fisher CJ;Recombinant human protein C Worldwide Evaluation in Severe Sepsis 《The New England journal of medicine》2001,344(10):699-709
BACKGROUND: Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis. METHODS: We conducted a randomized, double-blind, placebo-controlled, multicenter trial. Patients with systemic inflammation and organ failure due to acute infection were enrolled and assigned to receive an intravenous infusion of either placebo or drotrecogin alfa activated (24 microg per kilogram of body weight per hour) for a total duration of 96 hours. The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion. Patients were monitored for adverse events; changes in vital signs, laboratory variables, and the results of microbiologic cultures; and the development of neutralizing antibodies against activated protein C. RESULTS: A total of 1690 randomized patients were treated (840 in the placebo group and 850 in the drotrecogin alfa activated group). The mortality rate was 30.8 percent in the placebo group and 24.7 percent in the drotrecogin alfa activated group. On the basis of the prospectively defined primary analysis, treatment with drotrecogin alfa activated was associated with a reduction in the relative risk of death of 19.4 percent (95 percent confidence interval, 6.6 to 30.5) and an absolute reduction in the risk of death of 6.1 percent (P=0.005). The incidence of serious bleeding was higher in the drotrecogin alfa activated group than in the placebo group (3.5 percent vs. 2.0 percent, P=0.06). CONCLUSIONS: Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding. 相似文献
7.
Dr. M. L. Farina Italian Group on Intensive Care Evaluation 《European journal of clinical pharmacology》1987,31(5):507-512
Summary Clinically relevant events possibly attributable to drug exposure have been monitored prospectively over a period of six months in 27 general intensive care units. Fifty-four events attributed to drugs were reported in 51 patients during their stay in hospital, corresponding to an overall incidence of 1.35%. The behaviour of the physicians following attribution of the events to a prescribed drug is analyzed and discussed in detail with respect to its relationship to the quality and severity of the reaction, and the classes of drugs. Twenty-four of the 4537 monitored admissions during the six months were due to life-threatening emergencies linked to the administration of drugs (14) and radio-contrast media (10) (overall incidence 0.5%). While the clinical burden attributable to adverse drug reactions in Intensive Care Units appears to be relatively small, the analysis shows that there is ample room for a greater reduction in their incidence.
Coordinators: Drs M. L. Farina and G. Tognoni, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Dr F. Procaccio, Neurosurgical ICU, Ospedale Ca' Granda, Niguarda, Milan.Investigators: Drs G. Barusco, Rovigo; F. Bassi, Milan; L. Bianchetti, Torino; E. Carchietti, Udine; G. Chilloni, Reggio Emilia; G. Costantini, Savigliano (CN); P. Ferrero, Aosta; E. Geat, Trento; F. Gorgerino, Torino; A. Lusini, Empoli (FI); G. Mantovani, Ferrara; S. Marchi, Bologna; P. Marcovigi, Forli; G. Marraro, Merate (CO); F. Merlo, Vicenza; E. Pagni, Bagno a Ripoli (FI); R. Pellegrino, Cuneo; C. Peruselli, Milan; A. Piovesano, Pordenone; R. Rinaldo, Cremona; R. Ruggerini, Piacenza; S. Sammartino, Torino; A. Sartore, Cittadella (PD); A. Scaglioli, Carpi (MO); G. Scopa, Terni; G. Zeffiro, Treviso; P. Zuccoli, Parma 相似文献
8.
儿童是否允许作为健康受试参加药物动力学研究,目前存在较大分歧。本列出截然不同的两种观点,旨在防范这类研究在健康儿童的不适当实施,以保证其符合国际共认的伦理学要求。 相似文献
9.
目的 :探讨苯妥英 (DPH)神经发育毒性与胚胎脑组织中自由基产生和氧化应激反应的关系。方法 :Wistar孕鼠于妊娠d 11~ 14经 0 ,10 0 ,2 0 0mg·kg-1DPH或合并 4 0mg·kg-1褪黑素 (MT)染毒处理 ,研究MT对DPH的仔代反射功能发育及自发运动损害作用的拮抗效应。结果 :孕鼠在染毒期及染毒后增重下降 ,仔代体重减轻 ,哺乳期死亡率增高 ;DPH染毒仔鼠的转身运动增多 ,空中翻正反射及游泳能力发育延迟 ,成年后行走次数、站立次数、刻板动作等自发活动增多 ,旋转手比率增多 ,对阿朴吗啡“激发”反应性增强。MT和DPH合并处理可明显拮抗上述DPH仔鼠的行为异常。结论 :氧化性损伤在DPH神经发育毒性发生中发挥重要作用 ,而MT可拮抗其毒性作用。 相似文献
10.
目的 :评价疏可眠胶囊治疗失眠症 (肝气郁结证 )的有效性和安全性。方法 :采用分层分段随机、双盲、阳性药平行对照、多中心临床试验。选择失眠症 (肝气郁结证 )患者 4 40例 ,其中试验组 330例 ,给予疏可眠胶囊每次 4粒 ,每日 2次 ,晚饭后及临睡前各服 1次 ;对照组完成 110例 ,给予舒眠胶囊每次 3粒 ,每日 2次 ,晚饭后及临睡均各服 1次。治疗 2周后 ,评价有效性和安全性各种指标。结果 :用药 2周后对照组愈显率 4 0 .0 0 % (n =110 ) ,试验组愈显率5 8.0 5 % (n =32 9) ,试验组优于对照组 (P <0 .0 1) ,扣除中心效应结果相同。临床观察中未发现明显不良反应。结论 :疏可眠胶囊治疗失眠症 (肝气郁结证 ) ,安全有效 相似文献